Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Related Keywords

, Ibrutinib Combined With Venetoclax , Patients With , Refractory Mantle Cell Lymphoma , Primary Analysis Results From , Randomized Phase , Ibrutinib , Venetoclax , Cmcl , Mantle Cell Lymphoma , Rr Mcl , Relapsed Refractory Mantle Cell Lymphoma ,